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Abstract 
Pulmonary exposure to certain nanoparticles can induce lung inflammation and tissue damage 
characterized by neutrophil influx,elevated cytokine and total protein levels in bronchoalveolar 
lavage (BAL) fluid. In this study, measures of acute lung toxicity were assessed following 
single-dose intratracheal administration of nanoparticles with varying surface hydrophobicity 
(i.e. pegylated lipid nanocapsules, polyvinyl acetate nanoparticles and polystyrene beads; listed 
in order of increasing hydrophobicity). BAL fluid was collected from mice exposed to 
nanoparticles at a surface area dose of 220 cm
2 
and metabolite fingerprints were acquired via 
ultra pressure liquid chromatography-mass spectrometry-based metabolomics. Multivariate 
analysis of the resultant small molecule fingerprints revealed clear discrimination between the 
vehicle control and polystyrene beads (p<0.05), as well as between nanoparticles of low and high 
surface hydrophobicity (p<0.0001). Further investigation of the metabolic fingerprints revealed 
that adenosine monophosphate (AMP) concentration in BAL correlated with neutrophilia 
(p<0.01), CXCL1 levels (p<0.05) and nanoparticle surface hydrophobicity (p<0.001). Our results 
suggest that extracellular AMP is an intermediary metabolite involved in adenine nucleotide-
regulated neutrophilic inflammation and could potentially be used to monitor nanoparticle-
induced responses in the lung following pulmonary administration. 
 
Key words: Metabolomics, nanoparticles, lung, hydrophobicity, broncho-alveolar lavage (BAL), 
inflammation, AMP 
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Introduction 
When the lungs are exposed, either acutely or chronically, to nanosized materials 
inflammation and tissue damage can ensue.  The nature of the lung response is dependent on the 
type of material and the dose (Maynard et al. 2011). According to some classifications, 
nanomaterials may be divided into high and low toxicity materials based on their dose-response 
in the lungs (Fadeel et al. 2012; Aitken et al. 2009). High toxicity nanoparticles, which induce 
high levels of inflammation at low doses are generally composed of highly reactive materials, 
e.g. materials with significant positive or negative surface charge or materials that become toxic 
upon intracellular processing (Cho et al. 2012). In contrast, low toxicity nanomaterials (e.g. 
titanium dioxide, gold, silver, and polystyrene) tend to present a much more inert surface, hence 
they require much higher exposure doses to induce pulmonary inflammation (Duffin et al. 2007; 
Donaldson et al. 2008). This response to low toxicity nanoparticles is attributed primarily to the 
high material burden within a given tissue rather than nanomaterial reactivity (Maynard et al. 
2011). 
The majority of research investigating adverse effects of low toxicity nanomaterials has been 
conducted using rigid, crystalline, insoluble materials. There has been less research on the 
response of the respiratory system to the administration of organic nanomaterials (Dailey et al. 
2006; Nassimi et al. 2009; Harush-Frenkel et al. 2010; Liu et al., 2009; Beyerle et al. 2011), 
sometimes referred to as soft nanomaterials (Nalwa, 2009). Organic nanomaterials are 
increasingly being developed as inhaled nanomedicines or components of aerosol-based 
consumer products, e.g. hairsprays, cleaning products, and include nanoconstructs such as liquid 
crystals, proteins, nucleic acids, polymers, surfactants, micelles, or emulsions (Nalwa, 2009).  
These have very different physicochemical properties compared to rigid crystalline nanoparticles 
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and typically present an amorphous, more flexible surface that may be highly hydrated (Moghimi 
& Szebeni 2003; Lorusso et al. 2007; Maynard et al. 2011; Dailey, 2009). Hence, it is important 
to evaluate how the respiratory system responds to the physicochemistry presented by organic 
nanomaterials, especially when these are biopersistent. 
Surface hydrophobicity is one feature of many organic nanoparticles and has been implicated 
as a defining factor in how the lungs respond to their administration (Maynard et al. 2011; 
Beyerle et al. 2011). In this study, hydrophobic interaction chromatography (HIC) (Carstensen et 
al. 1991) was used to characterize five organic nanomaterials with increasing surface 
hydrophobicity. The nanomaterials included two different lipid nanocapsule (LNC) formulations, 
two types of polyvinyl acetate (PVAc) nanoparticles, and commercially available polystyrene 
beads as a control material to benchmark to the literature. Nanoparticles were administered 
intratracheally (i.t.) to mice. Bronchoalveolar lavage (BAL) fluid was collected at 24 h and 
evaluated for markers of inflammation and tissue damage. Neutrophil counts and cytokine levels 
in BAL confirmed that the nanoparticles induced an inflammatory response linked to increasing 
surface hydrophobicity, with responses similar to those reported for known inert nanomaterials 
(Dailey et al. 2006; Duffin et al. 2007; Brown et al. 2001). 
The primary aim and scope of this study was then to apply non-targeted metabolomics to 
assess whether nanoparticle-induced lung toxicity yields informative metabolite profiles in BAL 
fluid or generates putative markers of nanoparticle-induced toxicity. In metabolomics research, 
non-targeted investigations are conventionally performed in a phase one study to screen for 
differences in metabolite levels that indicate perturbations in normal metabolic pathways. The 
strength of this approach is that it is non-biased towards any particular outcome (i.e. non-
hypothesis driven) and may therefore identify putative markers of both known and previously 
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undiscovered metabolic pathways. Once metabolites of interest have been identified, targeted 
phase two studies are then designed to investigate specific pathways of interest, evaluate multiple 
compartments or perform longitudinal studies. In this non-targeted, metabolomics study, it was 
hypothesized that BAL fluid from vehicle control animals would differ significantly in 
metabolite profile compared to that of animals exposed to nanoparticles. Further, it was 
postulated that specific metabolites may be identified which correlate with the acute respiratory 
toxicity induced by nanoparticles of increasing surface hydrophobicity. 
 
Methods 
Polymer synthesis. Two grades of PVAc, high molecular weight (148kDa) and low molecular 
weight (12.8 kDa), were purchased from Sigma Aldrich, UK. The 148 kDa PVAc was subjected 
to direct saponification according to the method described by Chana and colleagues (Chana et al. 
2008) producing a modified PVAc polymer with 17 mol% hydroxyl groups and 83 mol% 
residual acetate groups (PVAc80). The 12.8 kDa PVAc polymer was subjected to direct 
saponification under different reaction conditions to produce a PVAc polymer with 34 mol% 
hydroxyl groups and 66% residual acetate groups (PVAc60) (Chana et al. 2008). Polymer purity 
and degree of hydrolysis were verified by NMR analysis prior to use. Poly vinyl alcohol (PVA; 
8-12 kDa; 80 mol% hydroxyl; 20 mol% acetate groups) was used a stabiliser in nanoparticle 
manufacture and was purchased from Sigma Aldrich, UK. 
Manufacture of PVAc nanoparticles. PVAc60 nanoparticles were prepared according to a 
method by Chana et al. (Chana et al. 2008) by injecting a solution of 5% w/v PVAc60 dissolved 
in 2:1 methanol:water into a 0.33 % w/v aqueous solution of the stabiliser, PVA, whilst stirring 
at 3500 rpm. PVAc80 nanoparticles were prepared by injecting a solution of 1% w/v PVAc80 
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dissolved in 2:1 methanol:water into a 0.33 % w/v aqueous solution of the stabiliser, PVA, whilst 
stirring at 3500 rpm. Following 30 min constant stirring at 4000 rpm and solvent evaporation 
overnight (~100 rpm), the nanosuspensions were dialysed against water (72 h) to remove excess 
PVA and subsequently concentrated to the desired final concentration using ultrafiltration 
centrifuge tubes (Millipore, UK; 100 kDa MWCO). Residual PVA was < 0.4-0.5 mg/mL.  
Particles were stored at 4°C and were used within one week of preparation. 
Manufacture of LNCs: 
 LNCs were manufactured using a phase-inversion temperature method (Heurtault et al. 2003). 
LNCs with a diameter of ~50 nm (LNC50) were prepared by generating a coarse emulsion of 
17% w/v Labrafac
®
 WL1349 (Gattefosse, Saint-Priest, France), 17.5% w/v Solutol
®
 HS15 
(BASF, Ludwigshafen, Germany), 1.75% w/v Lipoid
®
 S75-3 (Lipoid GmbH, Ludwigshafen, 
Germany) and 3% w/w NaCl in purified water. This emulsion was then submitted to repeated 
heating cooling cycles (85°-60°-85°-60°-85° C), before cooling to 72° C, at which point ice-cold 
water was added. Excess stabilizer (Solutol
®
 HS15) was removed from the suspension by 
dialysis (72 h) against water containing BioBeads
®
 (BioRad, Hertfordshire, UK) and subsequent 
concentration using ultrafiltration centrifuge tubes (Millipore, UK; 100 kDa MWCO). Residual 
Solutol HS 15 content was determined to be < 0.5 mg/mL. LNC with a diameter of ~150 nm 
(LNC150) were prepared and purified using the same method, except that the relative 
concentrations of the three main coarse emulsion components were: 25% w/v Labrafac WL1349, 
8.5% w/v Solutol
®
 HS15, 1.75% w/v Lipoid S75-3 (Lipoid GmbH, Ludwigshafen, Germany) 
and 3% w/w NaCl in purified water. Particles were stored at 4°C and were used within one week 
of preparation. 
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Polystyrene nanoparticles. Unmodified polystyrene nanoparticles with a diameter of 50 nm 
(PS50; 2.62% m/v) were used as a control and were purchased from Polysciences (Eppelheim, 
Baden-Württemberg, Germany). 
Nanoparticle size and surface charge. Particle size and zeta potential were determined using 
a Zetasizer Nano ZS (Malvern, Worcesterchire, UK). Particle suspensions were diluted in the test 
medium (purified water, 6.3 mM sodium chloride or Hank’s buffered saline solution containing 
10% fetal bovine serum) prior to measurement and the analysis parameters (viscosity, 
temperature, refractive index) were adjusted to match the medium and sample type used for 
analysis. 
Nanoparticle hydrophobicity: 
Surface hydrophobicity of nanoparticle suspensions (n=3 three individual batches) was 
assessed using HIC (Carstensen et al. 1991). Briefly, 250 μL nanoparticle suspension was 
prepared in phosphate-buffered saline (PBS) and eluted through three different HiTrap™ 
substituted sepharose hydrophobic interaction columns: Butyl FF, Phenyl FF (high substitution) 
and Octyl FF (GE Healthcare Life Sciences, Little Chalfont, UK). Fractions of 1 mL elutant were 
collected and analyzed for particle content via turbidity measurement (Lambda 35; Perkin-Elmer, 
Cambridge, UK; λ=450 nm). The column-bound particle fraction was subsequently eluted from 
the column using 0.1% Triton X-100 and turbidity measured. Absorbance values were plotted 
against elution volumes and two area under the curve (AUC) values were calculated using 
Origin™ software. The percentage particle retention in each of the three columns was defined as: 
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The HIC index value was calculated according to Equation (2): 
 
In the denominator, the 300% value represents the theoretical case of 100% retention on each 
column ideally achieved by a particle with maximum hydrophobicity. HIC index analysis was 
performed using a one way ANOVA comparison with a post-hoc Tukey test. p<0.05 was 
considered to be statistically significant. 
In vivo studies: 
 Male BALBc mice (6–8 weeks old, ~22 g; Charles River, UK) were used for in vivo 
pulmonary administration. All experiments were in accordance with the U.K. Home Office 
regulations and approved by the local ethics committee. Animals were divided in six groups 
(n=5-7) for treatment with either the vehicle control (5% dextrose; DEX) or nanoparticle 
suspensions. Dosing was spread across four different dates, with vehicle controls (1-2 animals) 
dosed at every session and 2-4 animals from different nanoparticle groups treated on a rotational 
basis. A theoretical nanoparticle surface area dose of 220 cm
2 
per instillation was chosen for 
study as this has been shown to induce a moderate inflammation in selected literature reports 
(Donaldson et al. 2000; Duffin et al. 2007). Particle surface area doses were calculated from the 
hydrodynamic diameter of the particles, assuming a density of ca. 1 g/cm
3 
for PVAc 
nanoparticles and 0.96 g/cm
3 
for LNC (estimated from the density of the oil which is the main 
constituent), and equated to ~200 μg nanoparticles per lung for the smaller LNC50 and PS 
systems and ~500 μg nanoparticles per lung for the larger LNC150, PVAc60, and PVAc80 
systems. All suspensions were prepared in dextrose 5% w/v to ensure isotonicity and colloidal 
stability and a 5% w/v dextrose solution was used as the vehicle control for all experiments. 
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Prior to i.t. dosing, animals were anaesthetized by inhaled isoflurane (1-3%) and maintained 
with an intraperitoneal injection of 100 mg/kg ketamine mixed with 20 mg/kg xylazine in 0.1 mL 
saline. This combination of tranquilizer/dissociative yielded a moderate level of anesthesia 
for 15-20 minutes, as assessed by paw pinch withdrawal reflex.  Mice were suspended at a 45° 
angle by their upper incisors and nanosuspensions (50L) were administered as a coarse aerosol 
into the lungs using a Penn Century Microsprayer
® 
aerosolizer (Penn-Century Inc. Wyndmoor, 
PA, USA). Animals were kept warm post-treatment with a heat lamp, then returned to their cages 
when ambulatory (<15 min). This administration method was chosen as it has been shown to 
achieve a more homogenous distribution of liquids into the lungs compared with conventional 
bolus i.t. instillation techniques (Bivas-Benita et al. 2005).   
Assessment of pulmonary inflammation in BAL: 
 Mice were euthanized via terminal anesthesia with urethane (2 mg/g i.p., Sigma Chemical 
Co.) 24 h after nanoparticle administration and a cannula was inserted into the exposed trachea. 
The lungs were lavaged with three aliquots (0.5 mL) of sterile saline that was recovered through 
the cannula. The total number of cells in the cellular fraction of the lavage was counted with a 
Neubauer haemocytometer (Fisher Scientific, Loughborough, UK). Differential cell counts were 
performed using cytospin preparations (i.e. 100 μL BAL cellular fraction centrifuged at 300 g for 
1 min using a Shandon Cytospin 2 (Shandon Southern Instruments, Sewickley, PA, USA) at 
room temperature). Cells were stained with Diffquick® (DADE Behring, Marburg, Germany) 
and a total of 200 cells were counted to determine the proportion of neutrophils, eosinophils and 
mononuclear cells using standard morphological criteria. Eosinophils were not observed in any 
sample and are not reported.  It was assumed that at the time point studied, the mononuclear cell 
population consisted primarily of resident alveolar macrophages and therefore lymphocyte 
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numbers were not investigated. Cytokines present in the BAL supernatant were quantified using 
a murine 7-plex pro-inflammatory cytokine assay (MSD
®
96-Well Multi-Spot Cytokine Assay; 
Meso-Scale Discovery, Gainsborough, MD, USA) coupled with an MSD reader, which measures 
cytokine content via electrochemiluminesce. Of the seven cytokines analyzed (IFN-γ, IL-1β, IL-
6, IL-10, IL-12p70, CXCL1 (KC/GRO/CINC), and TNF-α), IL-10 and IL-12p70 were below 
detectable limits and were therefore excluded from the study. As a measure of tissue integrity, 
total protein levels in BAL were quantified using a Quick Start™ Bradford Protein Assay (Bio-
Rad, Hemel Hempstead, UK) according to manufacturer’s instructions. A two-sided Mann-
Whitney test was used for the comparison of BAL neutrophil counts,  cytokine and protein levels 
in all samples exposed to nanoparticles compared to the vehicle control (5% dextrose). p<0.05 
was considered to be statistically significant. 
Sample preparation and UPLC-Q-ToF analysis: 
 Extra pure formic acid and LC-MS grade acetonitrile (ACN) and water were purchased from 
Fluka (Sigma-Adrich). Aliquots (400 μL) of BAL fluid samples (DEX, n=6; LNC50, n=7; 
LNC150, n=6; PVAc60, n=5; PVAc80, n=7; and PS, n=7) were transferred to clean tubes and 
evaporated to dryness at 100°C. Samples were reconstituted in 100 μL of 50:50 (v:v) purified 
water containing 0.1% formic acid and ACN containing 0.1% formic acid. Samples were vortex 
mixed for 1 min at room temperature. Quality control samples (n=5) consisted of samples 
without a pre-concentration step. These were used to verify retention time and mass during the 
duration of the analytical run (Whiley et al. 2012). Samples were run on a Waters Acquity 
coupled to a Waters Xevo QTOF-MS. The UPLC was performed on a Waters ACQUITY 
UPLC™ system, equipped with binary solvent delivery manager, sample manager and 
quadrupole time of flight mass spectrometer. Parameters were as listed: chromatographic column 
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(Garcia-Perez et al. 2010) UPLC-BEH C18, 2.1×100mm (Waters Corporation, USA); mobile 
phase A: H2O (0.1% formic acid) and B: ACN (0.1% formic acid); gradient analysis: 90% A and 
10% B isocratic for 0–5, 5–20 min gradient to 100% B, 20–25 min isocratic 100% B; flow rate: 
0.5mL/min; pressure circa 9000 psi. The MS was operated in the positive ion mode with a 
capillary voltage of 2.7 kV and a cone voltage of 50 V. The desolvation gas flow was 490 L/h at 
a temperature of 300°C and the cone gas flow was 10L/h. A source temperature of 100°C was 
used. All analyses were acquired using the lock spray to ensure accuracy and reproducibility; 
leucine enkephalin was used as lock mass (m/z 556.2771 Da) at a concentration of 200 ng/mL 
and a flow rate of 10μL/min. Data were collected in the centroid mode with a lock spray 
frequency of 11s over the mass range m/z 50–850 with an acquisition time of 250 ms, inter-scan 
delay of 50 ms. The chromatograms were obtained by injecting 4 µL. Sample sequences were 
assembled in blocks with blanks every seven injections to monitor for hydrophobic compound 
carry-over and QC samples were run to ensure analytical reproducibility. Identification of 
adenosine monophosphate (AMP) was made by first searching databases and then confirmation 
with MS-MS analyses of two AMP standard compounds (AMP 5’ and 3’ standards; Sigma-
Aldrich, UK). 
UPLC-Q-ToF data analysis: 
 UPLC-Q-ToF data were analyzed using Mass Lynx version 4.1, published by Waters 
Corporation, Massachusetts, USA, and exported to SIMCA-P™ software version 11.5, published 
by Umetrics AB, Umeå, Sweden. Data comprised 38 BAL samples, seven blanks and 4,753 
variables per chromatogram (each variable was a retention time and m/z). Models were created 
by normalizing to total chromatogram area and scaling variables to pareto in all principal 
component analyses (PCA), orthogonal partial least squares discriminant analyses (OPLS-DA) 
 13 
and partial least squares (PLS) analyses. PCA was used to assess quality controls and identify 
outliers in the groups. PLS detects the variation in the fingerprint data as a whole (x-block) and 
compares it with variation patterns in the metadata (e.g. discrimination, hydrophobicity, 
neutrophilia or cytokine levels; y-block).  PLS divides the analysis into two parts: one part 
models the covariation between the fingerprint patterns (R
2
X% is the percentage correlation of 
the metabolite fingerprints or goodness-of-fit) and the second part models correlation to metadata 
(R
2
Y%). The Q
2
 (%) or goodness-of-prediction value expressed the prediction power of the 
model and is the output of a seven-fold cross-validation. Two to three components were 
calculated for each model. Models were cross-validated independently by 100 fold scrambling 
and a CV-ANOVA test. Only features that showed high correlation to either treatment group 
were considered for identification and semi-quantification. 
Metabolite identification was achieved by database searching of in-house libraries and the 
Human Metabolome Database (HMDB; now containing 40,000 metabolite entries) for standard 
compounds and their molecular fragmentation pattern (Whiley et al. 2012; Xiayan & Legido-
Quigley 2008). A two-sided Mann Whitney test was used to assess significance of AMP 
measurements for all samples exposed to nanoparticles compared to the vehicle control. 
 
Results 
Manufacture of organic nanoparticles with low to high surface hydrophobicity  
Two discrete size classes of nanoparticles (~50 and 150 nm) were included in the study (Table 
1).  The sizes were dictated by the chemical composition and the manufacturing techniques used 
to produce the nanoparticles. The nanoparticles studied did not exhibit a pronounced surface 
charge and all nanoparticles were physically stable in purified water for up to four weeks. 
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LNC50, LNC150 and PVAc60 retained their original size in Hank’s buffered saline (HBSS) at 
37°C for over 24 h, but PVA80 and PS50 aggregated immediately upon addition to HBSS (Table 
1). 
The surface hydrophobicity of the nanoparticles was quantified using a HIC index scale (zero 
= hydrophilic, 1.00 = hydrophobic).  The nanoparticles studied spanned the upper 50% of the 
HIC index scale, ~0.60-0.96 (Figure 1). PS beads exhibited a nearly maximal hydrophobicity 
(0.96 ± 0.03) and therefore served as an excellent reference material.  The other nanoparticles 
used in the study exhibited a rank order of LNC50 < LNC150 < PVAc60 < PVAc80. Statistical 
analysis of the HIC values revealed two major groupings, low surface hydrophobicity particles 
(LNC50, LNC150 and PVAc60) and high surface hydrophobicity particles (PVAc80 and PS).  
 
Pulmonary toxicity of high surface hydrophobicity nanoparticles 
Neutrophilia and elevated pro-inflammatory cytokine levels were observed at significant 
levels in BAL for the two high hydrophobicity nanoparticle treatments, PVAc80 and PS (Figure 
2a,b,d). The moderate inflammation induced in response to PS nanoparticles correlated well with 
benchmark studies (Dailey et al. 2006; Donaldson et al. 2000; Duffin et al. 2007).  Total protein 
levels in BAL from nanoparticle treatment groups were not significantly different from the 
dextrose vehicle control, which may have resulted from the high variability in the vehicle control 
group.  Trends in the data suggest that high hydrophobicity nanoparticle treatment, especially PS 
exposure, generally resulted in higher BAL protein levels indicative of possible tissue damage. 
As noted above a high variability in both the inflammatory profile and BAL total protein 
content of the vehicle control (5% dextrose) was observed. Comparisons with untreated controls 
and animals administered 0.9% saline vehicle via an oral aspiration technique (Figure S1) 
provided evidence that the higher variability in the data may be linked to Microsprayer
®
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administration. Careful analysis showed that variability occurred randomly and potential outliers 
could not be correlated with factors such as animal batch, date of experiment or experience of the 
operator with the Microsprayer
®
 administration technique.  A further rationale for including 
putative outliers in the study was that it was of interest to examine whether the fingerprints of 
putative outliers showed metabolite patterns indicative of toxicity (i.e. similar to positive control 
profiles).   
 
Nanoparticle treatment results in significant differences in BAL metabolite fingerprints 
In this study, a total of 38 BAL fluid samples from the six treatment groups (vehicle control, 
nanoparticles, and quality control samples) were investigated. The fingerprints acquired 
consisted of chromatograms from which 4753 molecular features were extracted. In a 
preliminary analysis using PCA, quality controls were superimposable verifying analytical 
reproducibility. OPLS-DA was used to compare the fingerprint profiles of vehicle and PS- 
treated groups (Figure 3), which acted as negative and positive controls, respectively (Dailey et 
al. 2006; Duffin et al. 2007; Brown et al. 2001). The analysis discriminated between PS 
nanoparticle treatment and the vehicle control (p = 0.041), indicating that different metabolites 
dominated the fingerprints of lungs exposed to nanoparticles compared to those that were not.  
Five molecule masses (m/z 331.20, 284.95, 188.12, 182.18 and 174.10 Da) were identified from 
the model as unknown metabolites having the highest correlation (0.98 to 0.78) with PS exposure 
(elevated concentrations found in PS treated group compared to vehicle control). These five 
molecules did not correspond to any of the known accurate masses in metabolite databases and 
could not be identified within the scope of this study. 
OPLS-DA was also used to compare the BAL fingerprint profiles of animals exposed to low 
hydrophobicity (LNC50, LNC150 and PVAc60) versus high hydrophobicity (PVAc80 and PS) 
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nanoparticles (Figure 4). The analysis discriminated between the two HIC-index groupings 
(p<0.0001). Interestingly, all five unknown metabolites associated with PS NP exposure (m/z 
331.20, 284.95, 188.12, 182.18and 174.10 Da) were positively correlated in the high versus low 
HIC comparison model (correlation = 0.83 to 0.50; Figure 4) suggesting that these molecules 
may be interesting candidates to take forward into targeted,studies of biomarkers for high 
hydrophobicity nanoparticle exposure. 
Partial least squares (PLS) analysis was performed to analyze the incremental relationship 
between nanoparticle hydrophobicity, inflammatory outcomes and the BAL fingerprints. Total 
protein levels in BAL were excluded from PLS analysis due to their lack of significance between 
groups. Table 2 lists the PLS analysis metrics for covariance of fingerprint data and nanoparticle 
HIC index score, neutrophil counts or BAL CXCL1 concentration, while Figure 5 depicts the 
PLS score plot correlating to HIC index score. A substantial correlation between metabolite 
fingerprints and measures of lung inflammation (neutrophils and CXCL1) was indicated by the 
Q
2
 values of 65 and 68%, respectively.  The model for covariance between metabolite 
fingerprints and nanoparticle hydrophobicity showed a similar predictive Q
2
 value of 66%, 
indicative of the relationship between increasing nanoparticle hydrophobicity, lung inflammation 
and metabolite fingerprint models. 
Elevated AMP levels correlate with increasing HIC index score 
Analysis of the features that governed the correlation between metabolite fingerprint and HIC 
index identified a retention and mass of interest. Using standard compounds and fragmentation 
patterns (Esther et al. 2008b), AMP (m/z 348.06 Da with a main fragment observed at 136.06 
Da) was identified as a signature molecule associated with the effects generated in the lungs by 
nanoparticle of increasing hydrophobicity. The loading plot of the PLS model is provided in the 
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supplementary information Figure S2, showing the feature identified as AMP driving the trend 
towards PVAc-80 and PS seen in Figure 5. AMP was measured in all the chromatograms and 
validation of the molecule identity was performed with the pure compound (supplementary 
information Figure S3 showing MS-MS AMP identification). Scatter plots depicting paired 
values of AMP peak areas from the raw data against neutrophil numbers (Figure 6a) and total 
protein levels (Figure 6b) show that AMP levels are only elevated in BAL samples from high 
hydrophobicity nanoparticle treatment groups (data summarized in Figure 6c).  
Discussion 
The aims of this study were twofold: 1) to assess the impact of high vs. low nanoparticle 
surface hydrophobicity on lung toxicity and 2) to apply a non-targeted metabolomics strategy to 
investigate whether organic nanoparticle exposure would result in significantly differentiated 
BAL metabolite profiles and to identify putative markers of nanoparticle exposure.  Using 
conventional measures of pulmonary inflammation and tissue damage, it was demonstrated that 
nanoparticles of different composition exhibiting a high surface hydrophobicity (PVAc80 and 
PS) were pro-inflammatory and showed possible evidence of tissue damage, while low 
hydrophobicity nanomaterials (LNC50, LNC150 and PVAc60) induced little to no toxicity 
according to these parameters. Hydrophobic nanoparticle surface chemistries may induce 
pulmonary toxicity through more than one mechanism. For example, it has been shown that 
proteins and opsonins may absorb more favorably onto a hydrophobic surface, promoting 
recognition, uptake and inflammatory signaling by phagocytic cells (Ruge et al. 2012; Singh & 
Lillard 2009). A pertinent mechanism in this study may be particle aggregation in physiological 
fluids resulting in irregular surfaces, which have been associated with higher inflammatory 
potential than comparable smooth-surface particles (Vaine et al. 2013). Only the nanoparticles in 
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the high surface hydrophobicity group (PS50 and PVAc80) aggregated in isotonic buffer at 37˚C 
(Table 1), which may have contributed significantly to their enhanced inflammatory potential 
and possible tissue damage in vivo.  
 With the impact of nanoparticle surface hydrophobicity established using conventional 
parameters (aim 1) it was possible to undertake a non-targeted, phase one metabolomics study 
(aim 2) with the remaining BAL fluid from these study groups. Non-targeted, NMR-based 
metabolomics screening has been used in a handful of studies to date to analyse intact tissues 
(lung, liver), as well as biofluids such as urine, serum and BAL from test animals after 
pulmonary, oral or intravenous exposure to different nanomaterials, including copper oxide, 
silica and titanium dioxide (Hu et al. 2008; Bu et al. 2010; Lei et al. 2008; Lu et al. 2011). 
Notably, Hu et al. (2008) examined the pulmonary effects of i.t. administration of high dose 
silica nanoparticles one week and four months post-exposure.  Metabolites identified as highly 
correlated with silica exposure (both in BAL and lung tissue) were primarily associated with cell 
membrane damage (elevated cholines and phosphocholine species), as well as elevated levels of 
hydroxyproline, indicative of the typical fibrosis development associated with silicosis (Hu et al. 
2008). 
In this study, five unidentified metabolites and AMP were identified as candidate biomarkers 
of high hydrophobicity nanoparticle exposure.  While metabolite identification is of major 
importance for the design of hypothesis-driven mechanistic studies of toxicity, it must be 
emphasized that the identification process of unknown molecules from UPLC-MS 
chromatograms is not trivial, as current databases only hold metabolite mass and fragmentation 
pattern information on a small fraction of the estimated total number of possible metabolites 
(Whiley et al. 2012).  AMP, on the other hand, was identifiable from databases through its mass, 
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fragmentation pattern and subsequent validation using a pure standard substance. It was observed 
that AMP levels in BAL fluid correlated highly with increasing nanoparticle hydrophobicity and 
acute lung inflammation.  This observation was interesting as, in contrast to many putative 
biomarkers identified in non-targeted metabolomic screens, there is literature evidence to link 
AMP with known mechanisms of pulmonary toxicity.  Figure 7 outlines a hypothetical role for 
AMP in high hydrophobicity nanoparticle toxicity. 
Neutrophilic inflammation is known to be regulated by extracellular purine signaling. 
Activated neutrophils secrete high quantities of ATP, which acts as a chemotactic agent for 
further neutrophil recruitment to the site of inflammation (Jacob et al. 2013; Barletta et al. 2012).  
Elevated extracellular levels of ATP activate the purine receptors, P2X and P2Y subtypes, which 
are expressed across a wide range of cell types in the lung and specifically promote chemotaxis, 
release of pro-inflammatory cytokines, actin mobilization and enhanced phagocytosis, as well as 
respiratory burst events in neutrophils (Jacob et al. 2013; Barletta et al. 2012). Because of its 
potent pro-inflammatory effects, extracellular ATP is rapidly metabolized in the lung lining fluid 
to ADP, AMP and adenosine at the respiratory epithelial surface.  The lung mucosal surface 
possesses four major classes of enzymes to metabolize ATP to adenosine:  
ectonucleotidases:ecto-nucleotide pyrophosphatase/phosphodiesterases (E-NPP: ATP → AMP), 
alkaline phosphatases (AP: ATP → ADP → AMP → adenosine) and ecto-nucleoside 
triphosphate diphosphohydrolases (E-NTPDases: ATP → AMP) and ecto-5′-nucleotidase (eNT: 
AMP → adenosine) (Burch & Picher 2006; Robson et al. 2006). Currently, relatively little is 
known about the direct role of extracellular AMP in inflammation, except as an intermediate 
metabolite.  Adenosine, in contrast, is known to be both a pro-and anti-inflammatory signaling 
molecule.  For example, in neutrophils, adenosine binding to adenosine receptor subtypes A1 and 
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A3 generally promotes pro-inflammatory responses, while A2A and A2B activation results in anti-
inflammatory effects, such as reduction in pro-inflammatory cytokine release, phagocytosis and 
degranulation (Barletta et al. 2012; Blackburn et al. 2009; Reutershan, 2009). Thus, the 
regulation of neutrophil response in lung inflammation is controlled both by levels of 
extracellular signaling molecule levels, as well as differential purine and adenosine receptor 
expression patterns. 
The use of elevated extracellular purine levels as a putative biomarker for disease-induced 
neutrophilic inflammation has been reported previously. ATP and AMP have been observed to 
be elevated in BAL fluid samples from cystic fibrosis (CF) patients compared to disease controls 
(patients with unrelated respiratory disease) as well as in exhaled breath condensate from CF 
patients vs. healthy controls (Esther et al. 2009; Esther et al. 2008a; Wolak, 2009; Kavitha et al. 
2013). Further, a highly significant correlation (p<0.0001) between neutrophil counts and 
increases ATP and AMP was found for all samples irrespective of disease state, supporting the 
authors’ hypothesis that elevated ATP and AMP were a product of the secondary neutrophilic 
inflammation rather than the primary pathology (Esther et al. 2008a). Interestingly, it was also 
observed that AMP levels were consistently higher than those of ATP (Esther et al. 2008a), 
which was speculated by Esther et al. (2008a) to arise from increased metabolism of ATP to 
AMP by E-NTPDases (present on both neutrophils and epithelial cell surfaces) combined with a 
lower capacity to convert extracellular AMP to adenosine during inflammation due to a relative 
lack of 5′-nucleotidase (eNT: AMP → adenosine) on the surface of infiltrating neutrophils.  
It should be noted that while the studies described above were able to show a strong direct 
correlation between neutrophil numbers and AMP levels, as well as ATP levels (Esther et al. 
2009; Esther et al. 2008a; Wolak, 2009; Kavitha et al. 2013), our preliminary results do not 
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reveal a high direct correlation between neutrophil numbers and AMP peak areas in the raw data, 
even within the high hydrophobicity nanoparticle treatment group (Figure 6a).  One important 
reason for this discrepancy could be explained by the fact that the studies cited above all used 
optimized protocols to specifically measure ATP and AMP levels in their samples.  This is 
representative of a targeted, phase two approach in the biomarker development pathway.  In 
contrast, the standard analytical protocol used in this study was designed to maximize the 
detection of the largest number of unknown metabolites, and may not have favored purine 
detection. In fact, Esther et al. (2008b) report that higher polarity nucleotide species, such as 
ATP, can be sensitive to low pH mobile phases such as those used in this study (e.g. 0.1% formic 
acid pH 3-5) and this can have an effect on the limits of detection of the metabolite (Esther et al. 
2008b). AMP, a less polar metabolite, is more easily detected in a low pH mobile phase, but may 
still require further optimization for robust quantification. Thus, it should be emphasized that 
targeted, phase two studies using optimized analytical conditions to assess concurrent levels of 
ATP, ADP, AMP and adenosine and longitudinal experimental design are required to shed 
further light on the overall variation of extracellular purines in nanoparticle-induced acute lung 
inflammation and tissue damage. 
 
Conclusions 
This study has demonstrated that hydrophobic nanoparticles induced acute respiratory 
inflammation when administered into the lungs of mice.  The inflammation was characterized by 
significantly increased neutrophilia, elevated levels of pro-inflammatory cytokines, possible 
evidence of increased tissue damage and significantly altered metabolite fingerprints in BAL 
fluid. AMP concentration in BAL was found to correlate with the degree of inflammation 24 
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hours after administration of the nanoparticles, the time point of peak neutrophilic response. This 
finding supports the hypothesis that elevated extracellular purines in the lungs may be candidate 
biomarkers for neutrophilic lung inflammation. It is the first study to our knowledge to 
demonstrate elevated AMP in response to nanoparticle exposure.   
The non-targeted metabolomics screen also yielded five unidentified metabolites that were 
highly correlated with hydrophobic nanoparticle exposure.  The identities of these metabolites 
will be elucidated in future studies using isolation of molecules and LC-MS techniques 
combined with NMR analysis.  Similar to AMP, the identities of these molecules may shed 
further light on individual mechanisms of respiratory nanotoxicity and they have the potential to 
expand meaningfully the range of nanotoxicity biomarkers available to researchers today. 
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Figure captions 
Figure 1. Quantitative evaluation of nanoparticle surface hydrophobicity expressed as the HIC 
index score of five nanomaterials. Values represent the mean ± standard deviation of n=3 
individual nanoparticle batches. * p< 0.05 
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Figure 2. Assessment of pulmonary toxicity 24 h post intratracheal administration of five 
nanomaterials based on (a) neutrophil counts, (b) total cells, (c) total protein levels and (d) pro-
inflammatory cytokine content in BAL fluid (n=5-7 individual animals per group). * p< 0.05, ** 
p<0.01. 
Figure 3. OPLS-DA scores plot of the vehicle control (5% dextrose solution) and positive 
control (PS nanoparticle exposure) showing group separation (p = 0.041). 
Figure 4. OPLS-DA scores plot of the low hydrophobicity nanoparticle treatment groups 
(LNC50, LNC150 and PVAc60) and high hydrophobicity nanoparticle treatment groups 
(PVAc80 and PS) showing group separation (p-value< 0.0001). 
Figure 5: PLS scores plot showing the relationship between individual nanoparticle fingerprints 
and HIC index values. The figure also shows the direction of an identified metabolite, AMP, 
which follows the trend of inflammation. 
Figure 6. Semi-quantitative analysis of AMP levels. (a) AMP(peak area normalized to total 
fingerprint area) is plotted against paired values for the number of neutrophils in BAL, (b) AMP 
(peak area normalized to total fingerprint area) is plotted against paired values for the protein 
content in BAL, (c) AMP (peak area normalized to total fingerprint area) levels from vehicle 
control, low hydrophobicity and high hydrophobicity nanoparticle treatment groups.  *p<0.05, 
** p<0.01, *** p<0.001. 
Figure 7. A summary diagram outlining hypothetical mechanisms which may be involved in 
observed increased levels of extracellular purines following exposure to high hydrophobicity 
nanoparticles.  The simplified diagrams of extracellular ATP metabolism are based on 
information contained in (Burch & Picher 2006; Robson et al. 2006, Barletta et al. 2012; 
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Blackburn et al. 2009). E-NPP = Ecto-nucleotide pyrophosphatase/phosphodiesterases; AP = 
alkaline phosphatases; E-NTPDase = ecto-nucleoside triphosphate diphosphohydrolases; eNT = 
ecto-5′-nucleotidase; ADA = adenosine deaminase; ADK = adenosine kinase.   
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Table 1. Composition and physicochemical properties of the five organic nanoparticles studied.  
 Lipid nanocapsules  Polymeric nanoparticles 
Abbreviation LNC50 LNC150 PVAc60 PVAc80 PS 
Nanoparticle 
core  
90% TG 93% TG 
 99% 
PVAc60 
96% 
PVAc80 
Polystyrene 
Nanoparticle 
stabilizer  
0.3% PEG-HS 
9.3% PC 
0.2% PEG-HS 
6.5% PC 
 
0.8% PVA 3.8% PVA Undisclosed 
Diameter (nm) 40 ± 3 143 ± 2  160 ± 7 165 ± 7 54 ± 4 
PDI 0.14 ± 0.02 0.32 ± 0.42  0.13 ± 0.03 0.08 ± 0.03 0.04 ± 0.02 
ζ (mV) -7 ± 4 -4 ±1  -3 ± 1 -4 ± 1 -25 ± 5 
Stability in 
H2O (4°C) 
> 4 weeks > 4 weeks 
 
> 4 weeks > 4 weeks > 4 weeks 
Stability in 
HBSS (37°C) 
>24 h >24 h 
 
>24 
Immediate 
aggregation 
Immediate 
aggregation 
Table abbreviations: PEG-HS= polyethylene glycol660a-(15)-hydroxystearate; PC=soy lecithin; TG= 
medium chain triglycerides; PVA= polyvinyl alcohol; PVAc= polyvinyl acetate; PDI= polydispersity 
index; ζ= zeta potential 
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Table 2.PLS analyses to assess correlations between BAL small molecule fingerprints and 
nanoparticle hydrophobicity (HIC index), neutrophil count or BAL CXCL1 concentration.  The 
R
2
X, R
2
Y and Q
2
 values are provided for each model in percentage. 
 HIC Index Neutrophils CXCL1 
R
2
X (%) 28 28 29 
R
2
Y (%) 98 97 98 
Q
2 
(%) 66 65 68 
P-value 0.001 0.01 0.04 
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